Aggressive Smoking Cessation Trial (ASAP)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 798 participants.

Also called NCT05257629

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 798 participants (planned count) (from the registry)
Sponsor
Sir Mortimer B. Davis - Jewish General Hospital (from the registry)
Registry
  • NCT NCT05257629
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05257629. Randomized; no masking; primary purpose prevention. Start 2023-02-02 (actual); primary completion 2026-03-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Aggressive Smoking Cessation Trial (ASAP)
Acronym
ASAP
Condition
Acute Coronary Syndrome
Condition
Cardiovascular Diseases
Intervention (Combination product)
Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)
Intervention (Other)
Varenicline Plus Counseling
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital (class: other)

Record details

Record id
cardio:ct-nct05257629
Content hash
cccbc5fe3eb0a49e53b15edf95316f69de50fbefcdd4aa4dc2dbf9e5467b5f44